The last 2 decades have seen significant progress in identifying diverse genetic driver mutations in AML and in developing therapies directed against those mutations, such as inhibitors of FLT3 (FMS-related tyrosine kinase 3), IDH1/IDH2 (Isocitrate dehydogenase 1/2), BCL-2, and MENIN, and epigenetic modifiers.2 Here, BCL2 is linked to acute myeloid leukemia.